New combo therapy shows promise for rare blood cancer
NCT ID NCT02717624
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 23 times
Summary
This early-phase study tests a new drug combination for people with untreated mantle cell lymphoma, a rare blood cancer. Participants receive acalabrutinib plus either bendamustine and rituximab or venetoclax and rituximab. The main goal is to check safety and side effects, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Louisville, Kentucky, 40207, United States
-
Research Site
Ann Arbor, Michigan, 48109, United States
-
Research Site
Hackensack, New Jersey, 07601, United States
-
Research Site
Morristown, New Jersey, 07960, United States
-
Research Site
Lake Success, New York, 11042, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Seattle, Washington, 98109, United States
-
Research Site
Seattle, Washington, 98122, United States
-
Research Site
Bologna, 40138, Italy
-
Research Site
Krakow, 30-510, Poland
-
Research Site
Lodz, 93-510, Poland
-
Research Site
Olsztyn, 10-228, Poland
-
Research Site
Warsaw, 02-106, Poland
Conditions
Explore the condition pages connected to this study.